ADPT vs ALC
Adaptive Biotechnologies Corporation vs Alcon Inc — AI-powered side-by-side comparison
ADPT
Adaptive Biotechnologies Corporation
59
Watch
VS
| Metric | ADPT | ALC |
|---|
| AI Score |
59
|
68
|
| Price |
$25.39
|
$75.39
|
| P/E Ratio |
-62.32×
|
45.39×
|
| ROE |
-27.2%
|
4.4%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.4%
|
54.9%
|
| Debt / Equity |
2.87×
|
0.24×
|
| Dividend Yield |
0.0%
|
0.5%
|
| RSI (14) |
67.3
|
73.4
|
| Beta |
2.088
|
0.703
|
| Expected Upside |
—
|
+11.3%
|
AI Committee View
Current Innellis committee reasoning for ADPT versus ALC.
ALC leads by 9 points.
ALC scores 68/100 (Buy) versus ADPT at 59/100 (Watch).
ADPT Committee View
50% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 50.1% yoy -- genuine top-line momentum. Value Analyst remains cautious — price-to-book of 11.3x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 50.1% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Price-to-book of 11.3x prices in significant intangible value — Value
- ROE of only -32.6% -- cheap may mean cheap for a reason — Value
- Weekly RSI at 85 -- overbought on the larger timeframe too — Technical
ALC Committee View
75% agreement
4 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is rsi at 73 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- RSI at 73 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical